WINT (Windtree Therapeutics) Other Long-Term Liabilities: $3.81 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Other Long-Term Liabilities?

Windtree Therapeutics WINT +100.00% Other Long-Term Liabilities is $3.81 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Windtree Therapeutics's other long-term liabilities for the quarter that ended in Sep. 2025 was $3.81 Mil.

Windtree Therapeutics's quarterly other long-term liabilities increased from Mar. 2025 ($4.84 Mil) to Jun. 2025 ($7.04 Mil) but then declined from Jun. 2025 ($7.04 Mil) to Sep. 2025 ($3.81 Mil).

Windtree Therapeutics's annual other long-term liabilities stayed the same from Dec. 2022 ($18.80 Mil) to Dec. 2023 ($18.80 Mil) but then declined from Dec. 2023 ($18.80 Mil) to Dec. 2024 ($6.98 Mil).

Windtree Therapeutics Other Long-Term Liabilities Related Terms

Windtree Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Other Long-Term Liabilities Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.80 18.80 18.80 18.80 6.98

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 6.98 4.84 7.04 3.81

Windtree Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $3.81 Mil mean?
Windtree Therapeutics (WINT) has a Other Long-Term Liabilities of $3.81 Mil as of Sep. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Windtree Therapeutics and its competitors.
Is Windtree Therapeutics' Other Long-Term Liabilities too high?
Windtree Therapeutics' current Other Long-Term Liabilities is $3.81 Mil.
How does Windtree Therapeutics' Other Long-Term Liabilities compare to VRTX and REGN?
Windtree Therapeutics' Other Long-Term Liabilities of $3.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Windtree Therapeutics and its competitors. Windtree Therapeutics's current Other Long-Term Liabilities is $3.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Other Long-Term Liabilities of $3.81 Mil. The current Other Long-Term Liabilities is $3.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Other Long-Term Liabilities is $3.81 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.